The latest reports on androgenetic alopecia
DOI:
https://doi.org/10.12775/QS.2024.18.53484Keywords
androgenetic alopecia, alopecia, dermatologyAbstract
Androgenetic alopecia (AGA) is the most common type of hair loss among women and men.
AGA is caused by a combination of genetic factors resulting in sensitivity to dihydrotestosterone (DHT), which binds to the androgen receptor (AR), mediating a series of biomolecular changes that lead to changes in the hair. There are many mechanisms that can lead to AGA, some of which remain undiscovered. Treatment of AGA is also important for psychological reasons, as it constitutes a significant psychosocial stressor in the lives of people affected by this disease and worsens the quality of life. The only medications approved for the treatment of AGA are oral finasteride and topical minoxidil. These drugs may be associated with side effects, hence the need to look for other treatment methods, especially for patients who cannot tolerate approved methods. The current review focuses on the latest reports on the pathogenesis and treatment of androgenetic alopecia.
References
Deng Y, Wang M, He Y, Liu F, Chen L, Xiong X. Cellular Senescence: Aging and
Androgenetic Alopecia. Dermatology. 2023;239(4):533-541. doi: 10.1159/000530681. Epub
Apr 22. PMID: 37088073.
Rudnicka L, Olszewska M, Rakowska A, Sar-Pomian M, Contemporary dermatology,
vol. 2, Warszawa 2022, pp. 119-122
Liu LP, Wariboko MA, Hu X, Wang ZH, Wu Q, Li YM. Factors associated with early-
onset androgenetic alopecia: A scoping review. PLoS One. 2024 Mar 7;19(3):e0299212. doi:
1371/journal.pone.0299212. PMID: 38451966; PMCID: PMC10919688.
Kasumagic-Halilovic E. Trichoscopic Findings in Androgenetic Alopecia. Med Arch.
Apr;75(2):109-111. doi: 10.5455/medarh.2021.75.109-111. PMID: 34219869; PMCID:
PMC8228579.
Oiwoh SO, Akinboro AO, Olayemi O, Salawu AA, Olasode OA, Onayemi EO.
Androgenetic alopecia: Traditional cardiovascular risk factors, metabolic syndrome, and
component traits among Nigerian adults. Niger J Clin Pract. 2023 Apr;26(4):463-469. doi:
4103/njcp.njcp_530_22. PMID: 37203111.
Moon IJ, Yoon HK, Kim D, Choi ME, Han SH, Park JH, Hong SW, Cho H, Lee DK,
Won CH. Efficacy of Asymmetric siRNA Targeting Androgen Receptors for the Treatment
of Androgenetic Alopecia. Mol Pharm. 2023 Jan 2;20(1):128-135. doi:
1021/acs.molpharmaceut.2c00510. Epub 2022 Nov 9. PMID: 36352823; PMCID:
PMC9812025.
Chen CL, Huang WY, Wang EHC, Tai KY, Lin SJ. Functional complexity of hair
follicle stem cell niche and therapeutic targeting of niche dysfunction for hair
regeneration. J Biomed Sci. 2020 Mar 14;27(1):43. doi: 10.1186/s12929-020-0624-8.
PMID: 32171310; PMCID: PMC7073016.
Li K, Sun Y, Liu S, Zhou Y, Qu Q, Wang G, Wang J, Chen R, Fan Z, Liu B, Li Y, Mao
X, Hu Z, Miao Y. The AR/miR-221/IGF -1 pathway mediates the pathogenesis of
androgenetic alopecia. Int J Biol Sci. 2023 Jun 26;19(11):3307-3323. doi:
7150/ijbs.80481. PMID: 37496996; PMCID: PMC10367565.
Deng Z, Chen M, Liu F, Wang Y, Xu S, Sha K, Peng Q, Wu Z, Xiao W, Liu T, Xie H, Li
J. Androgen Receptor-Mediated Paracrine Signaling Induces Regression of Blood Vessels in
the Dermal Papilla in Androgenetic Alopecia. J Invest Dermatol. 2022 Aug;142(8):2088-
e9. doi: 10.1016/j.jid.2022.01.003. Epub 2022 Jan 14. PMID: 35033537.
Choi BY. Targeting Wnt/β-Catenin Pathway for Developing Therapies for Hair Loss. Int
J Mol Sci. 2020 Jul 12;21(14):4915. doi: 10.3390/ijms21144915. PMID: 32664659; PMCID:
PMC7404278.
Ryu YC, Park J, Kim YR, Choi S, Kim GU, Kim E, Hwang Y, Kim H, Han G, Lee
SH, Choi KY. CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD2. Cells.
Feb 9;12(4):555. doi: 10.3390/cells12040555. PMID: 36831222; PMCID:
PMC9954685.
Liu Q, Tang Y, Huang Y, Wang J, Yang K, Zhang Y, Pu W, Liu J, Shi X, Ma Y, Ni C,
Zhang Y, Zhu Y, Li H, Wang J, Lin J, Wu W . Insights into male androgenetic alopecia using
comparative transcriptome profiling: hypoxia-inducible factor-1 and Wnt/β-catenin signaling
pathways. Br J Dermatol. 2022 Dec;187(6):936-947. doi: 10.1111/bjd.21783. Epub 2022 Sep
PMID: 35862273; PMCID: PMC10087000.
Cuevas-Diaz Duran R, Martinez-Ledesma E, Garcia-Garcia M, Bajo Gauzin D,
Sarro-Ramírez A, Gonzalez-Carrillo C, Rodríguez-Sardin D, Fuentes A, Cardenas-Lopez
A. The Biology and Genomics of Human Hair Follicles: A Focus on Androgenetic
Alopecia. Int J Mol Sci. 2024 Feb 22;25(5):2542. doi: 10.3390/ijms25052542. PMID:
; PMCID: PMC10932098.
Aukerman EL, Jafferany M. The psychological consequences of androgenetic alopecia:
A systematic review. J Cosmet Dermatol. 2023 Jan;22(1):89-95. doi: 10.1111/jocd.14983.
Epub 2022 Apr 25. PMID: 35403805; PMCID: PMC10084176.
Müller Ramos P, Melo DF, Radwanski H, de Almeida RFC, Miot HA. Female-pattern
hair loss: therapeutic update. An Bras Dermatol. 2023 Jul-Aug;98(4):506-519. doi:
1016/j.abd.2022.09.006. Epub 2023 Mar 30. PMID: 37003900; PMCID: PMC10334345.
Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Relative Efficacy of
Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male
Patients: A Network Meta-analysis. JAMA Dermatol. 2022 Mar 1;158(3):266-274. doi:
1001/jamadermatol.2021.5743. PMID: 35107565; PMCID: PMC8811710
Traish AM. Post-finasteride syndrome: a surmountable challenge for experience. Fertil
Steril. 2020 Jan;113(1):21-50. doi: 10.1016/j.fertnstert.2019.11.030. PMID: 32033719.
Lee S, Lee YB, Choe SJ, Lee WS. Adverse Sexual Effects of Treatment with Finasteride
or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.
Acta Derm Venereol. 2019 Jan 1;99(1):12-17. doi: 10.2340/00015555-3035. PMID:
Nobari NN, Roohaninasab M, Sadeghzadeh-Bazargan A, Goodarzi A, Behrangi E,
Nikkhah F, Ghassemi M. A systematic review of clinical trials using single or combination
therapy of oral or topical finasteride for women in reproductive age and postmenopausal
women with hormonal and nonhormonal androgenetic alopecia. Adv Clin Exp Med. 2023
Jul;32(7):813-823. doi: 10.17219/acem/157990. PMID: 36897103.
Iamsumang W, Leerunyakul K, Suchonwanit P. Finasteride and Its Potential for the
Treatment of Female Pattern Hair Loss: Evidence to Date. Drug Des Devel Ther. 2020
Mar 2;14:951-959. doi: 10.2147/DDDT.S240615. PMID: 32184564; PMCID:
PMC7060023.
Piraccini BM, Blume-Peytavi U, Scarci F, Jansat JM, Falqués M, Otero R, Tamarit
ML, Galván J, Tebbs V, Massana E; Topical Finasteride Study Group. Efficacy and
safety of topical finasteride spray solution for male androgenetic alopecia: a phase III,
randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022 Feb;36(2):286-
doi: 10.1111/jdv.17738. Epub 2021 Oct 25. Erratum in: J Eur Acad Dermatol
Venereol. 2023 Feb;37(2):452. PMID: 34634163; PMCID: PMC9297965.
Herz-Ruelas ME, Álvarez-Villalobos NA, Millán-Alanís JM, de León-Gutiérrez H,
Ocampo-Garza SS, Gómez-Flores M, Grimalt R. Efficacy of Intralesional and Oral
Dutasteride in the Treatment of Androgenetic Alopecia: A Systematic Review . Skin
Appendage Disorder. 2020 Nov;6(6):338-345. doi: 10.1159/000510697. Epub 2020 Oct
PMID: 33313048; PMCID: PMC7706484.
Reguero-Del Cura L, Durán-Vian C, de Quintana-Sancho A. RF-Mesotherapy With
Dutasteride: A Future Alternative Treatment for Androgenetic Alopecia. Actas
Dermosifiliogr (Engl Ed). 2020 Jun;111(5):419-420. English, Spanish. doi:
1016/j.ad.2018.10.030. Epub 2020 May 13. PMID: 32416936.
Zhou Z, Song S, Gao Z, Wu J, Ma J, Cui Y. The efficacy and safety of dutasteride
compared with finasteride in treating men with androgenetic alopecia: a systematic review
and meta-analysis. Clin Interv Aging. 2019 Feb 20;14:399-406. doi: 10.2147/CIA.S192435.
PMID: 30863034; PMCID: PMC6388756.
Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders:
a review. Drug Des Devel Ther. 2019 Aug 9;13:2777-2786. doi: 10.2147/DDDT.S214907.
Erratum in: Drug Des Devel Ther. 2020 Feb 10;14:575. PMID: 31496654; PMCID:
PMC6691938.
Shen Y, Zhu Y, Zhang L, Sun J, Xie B, Zhang H, Song X. New Target for Minoxidil in
the Treatment of Androgenetic Alopecia. Drug Des Devel Ther. 2023 Aug 24;17:2537-2547.
doi: 10.2147/DDDT.S427612. PMID: 37645625; PMCID: PMC10461613.
Parisi GF, Leonardi S, Ciprandi G, Corsico A, Licari A, Miraglia Del Giudice M, Peroni
D, Salpietro C, Marseglia GL. Cetirizine use in childhood: an update of a friendly 30-year
drug. Clin Mol Allergy. 2020 Feb 26;18:2. doi: 10.1186/s12948-020-00118-5. PMID:
; PMCID: PMC7043022.
Hossein Mostafa D, Samadi A, Niknam S, Nasrollahi SA, Guishard A, Firooz A.
Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male
Alopecia: A Randomized, Single-blind Controlled Study. J Pharm Pharm Sci. 2021;24:191-
doi: 10.18433/jpps31456. PMID: 33909554.
Bassiouny EA, El-Samanoudy SI, Abbassi MM, Nada HR, Farid SF. Comparison
between topical cetirizine with minoxidil versus topical placebo with minoxidil in female
androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Arch Dermatol
Res. 2023 Jul;315(5):1293-1304. doi: 10.1007/s00403-022-02512-2. Epub 2022 Dec 26.
PMID: 36571611; PMCID: PMC10205881.
Paichitrojjana A, Paichitrojjana A. Platelet Rich Plasma and Its Use in Hair Regrowth: A
Review. Drug Des Devel Ther. 2022 Mar 10;16:635-645. doi: 10.2147/DDDT.S356858.
PMID: 35300222; PMCID: PMC8922312.
GETKA Beata, PRZYBOROWSKA Kinga, RUKAT Mateusz, ŁATA Michał,
KWIECIEŃ Justyna and WIEJAK Katarzyna. Platelet-rich plasma therapy in the treatment of
androgenic alopecia – review. Journal of Education, Health and Sport. Online. 19 January
Vol. 53, pp. 187-197. DOI 10.12775/JEHS.2024.53.014.
Cruciani M, Masiello F, Pati I, Marano G, Pupella S, De Angelis V. Platelet-rich plasma
for the treatment of alopecia: a systematic review and meta-analysis. Blood Transfusion.
Jan;21(1):24-36. doi: 10.2450/2021.0216-21. Epub 2021 Nov 15. PMID: 34967722;
PMCID: PMC9918380.
Gentile P, Garcovich S. Systematic Review of Platelet-Rich Plasma Use in Androgenetic
Alopecia Compared with Minoxidil®, Finasteride®, and Adult Stem Cell-Based Therapy. Int
J Mol Sci. 2020 Apr 13;21(8):2702. doi: 10.3390/ijms21082702. PMID: 32295047; PMCID:
PMC7216252.
Pakhomova EE, Smirnova IO. Comparative Evaluation of the Clinical Efficacy of PRP-
Therapy, Minoxidil, and Their Combination with Immunohistochemical Study of the
Dynamics of Cell Proliferation in the Treatment of Men with Androgenetic Alopecia. Int J
Mol Sci. 2020 Sep 6;21(18):6516. doi: 10.3390/ijms21186516. PMID: 32899959; PMCID:
PMC7555524.
de Oliveira AFQ, Arcanjo FPN, Rodrigues MRP, Rosa E Silva AA, Hall PR. Use of
autologous platelet-rich plasma in androgenetic alopecia in women: a systematic review and
meta-analysis. J Dermatologist Treat. 2023 Dec;34(1):2138692. doi:
1080/09546634.2022.2138692. Epub 2022 Oct 31. PMID: 36264022.
Mercuri SR, Paolino G, Di Nicola MR, Vollono L. Investigating the Safety and Efficacy
of Platelet-Rich Plasma (PRP) Treatment for Female Androgenetic Alopecia: Review of the
Literature. Medicina (Kaunas). 2021 Mar 25;57(4):311. doi: 10.3390/medicina57040311.
PMID: 33806169; PMCID: PMC8066895.
Emer J. Platelet-Rich Plasma (PRP): Current Applications in Dermatology. Skin
Therapy Lett. 2019 Sep;24(5):1-6. PMID: 31584784.
Borba A, Matayoshi S, Rodrigues M. Avoiding Complications on the Upper Face
Treatment With Botulinum Toxin: A Practical Guide. Aesthetic Plast Surg. 2022
Feb;46(1):385-394. doi: 10.1007/s00266-021-02483-1. Epub 2021 Aug 2. PMID:
; PMCID: PMC8328485.
SZCZURASZEK Hugo, SZCZURASZEK, Paulina SAŁATA, Piotr, OLKO Paweł,
PALUCH, Michał, LICAK, Gabriela, ŻUCHNIK, Magda, BĘTKOWSKA, Paulina,
RADULSKI, Jakub and RYBKOWSKA, Agnieszka. Treatment of hyperhidrosis and the role
of Botulinum Toxin Type A in therapy - a literature review. Quality in Sport. Online. 21
March 2023. Vol. 10, pp. 41-51. DOI 10.12775/QS.2023.10.01.004.
Zhou Y, Yu S, Zhao J, Feng X, Zhang M, Zhao Z. Effectiveness and Safety of
Botulinum Toxin Type A in the Treatment of Androgenetic Alopecia. Biomed Res Int 2020
Aug 4;2020:1501893. doi: 10.1155/2020/1501893. PMID: 32802833; PMCID:
PMC7424364.
Devjani S, Ezemma O, Kelley KJ, Stratton E, Senna M. Androgenetic Alopecia:
Therapy Update. Drugs. 2023 Jun;83(8):701-715. doi:10.1007/s40265-023-01880-x.
Epub 2023 May 11. PMID: 37166619; PMCID: PMC10173235.
Martínez-Pizarro S. Low-Level Laser Therapy for Androgenetic Alopecia. Actas
Dermosifiliogr (Engl Ed). 2021 Feb;112(2):99-102. English, Spanish. doi:
1016/j.ad.2020.03.010. Epub 2020 Oct 29. PMID: 33130013.
Zakrzewski W, Dobrzyński M, Szymonowicz M, Rybak Z. Stem cells: past, present,
and future. Stem Cell Res Ther. 2019 Feb 26;10(1):68. doi: 10.1186/s13287-019-1165-5.
PMID: 30808416; PMCID: PMC6390367.
Liu D, Xu Q, Meng X, Liu X, Liu J. Status of research on the development and
regeneration of hair follicles. Int J Med Sci. 2024 Jan 1;21(1):80-94. doi:
7150/ijms.88508. PMID: 38164355; PMCID: PMC10750333.
Mao Y, Liu P, Wei J, Xie Y, Zheng Q, Li R, Yao J. Cell Therapy for Androgenetic
Alopecia: Elixir or Trick? Stem Cell Rev Rep. 2023 Aug;19(6):1785-1799. doi:
1007/s12015-023-10532-2. Epub 2023 Jun 5. PMID: 37277541; PMCID:
PMC10390634.
Krefft-Trzciniecka K, Piętowska Z, Nowicka D, Szepietowski JC. Human Stem Cell
Use in Androgenetic Alopecia: A Systematic Review. Cells. 2023 Mar 21;12(6):951. doi:
3390/cells12060951. PMID: 36980291; PMCID: PMC10047891.
Cai Y, Jia Z, Zhang Y, Kang B, Chen C, Liu W, Li W, Zhang W. Cell-free fat extract
restores hair loss: a novel therapeutic strategy for androgenetic alopecia. Stem Cell Res Ther.
Aug 23;14(1):219. doi: 10.1186/s13287-023-03398-1. PMID: 37612726; PMCID:
PMC10464375.
Völker JM, Koch N, Becker M, Klenk A. Caffeine and Its Pharmacological Benefits in
the Management of Androgenetic Alopecia: A Review. Skin Pharmacol Physiol.
;33(3):93-109. doi: 10.1159/000508228. Epub 2020 Jun 29. PMID: 32599587.
Milani M, Colombo F; GFM-O-Trial Investigators Group: Chiara Baraldo (Padova),
Mauro Barbareschi (Milano), Paolo Chieco (Ruvo di Puglia), Laura Colonna (Roma), Mandel
Victor Desmond (Modena), Maria Cristina Fiorucci (Genova). Efficacy and tolerability of an
oral supplement containing amino acids, iron, selenium, and marine hydrolyzed collagen in
subjects with hair loss (androgenetic alopecia, AGA or FAGA or telogen effluvium). A
prospective, randomized, 3-month, controlled, assessor-blinded study. Skin Res Technol.
Jun;29(6):e13381. doi: 10.1111/srt.13381. PMID: 37357646; PMCID: PMC10240182.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Anna Łopuszyńska, Łukasz Ochyra
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 211
Number of citations: 0
